MAP2K7 and non-small cell lung carcinoma: Our initial data supports that most acute anti-apoptotic adaptations can be prevented in vitro and in vivo (Figs. 3 and 4), demonstrating their potential for future clinical trials such as the combination of navitoclax with the MEK inhibitor trametinib (NCT02079740) or with the EGFR inhibitor osimertinib (NCT02520778) in advanced NSCLC tumors.